Spermidine as a target for cancer therapy

Pharmacol Res. 2020 Sep:159:104943. doi: 10.1016/j.phrs.2020.104943. Epub 2020 May 24.

Abstract

Spermidine, as a natural component from polyamine members, is originally isolated from semen and also existed in many natural plants, and can be responsible for cell growth and development in eukaryotes. The supplementation of spermidine can extend health and lifespan across species. Although the elevated levels of polyamines and the regulation of rate-limiting enzymes for polyamine metabolism have been identified as the biomarkers in many cancers, recent epidemiological data support that an increased uptake of spermidine as a caloric restriction mimic can reduce overall mortality associated with cancers. The possible mechanisms between spermidine and cancer development may be related to the precise regulation of polyamine metabolism, anti-cancer immunosurveillance, autophagy, and apoptosis. Increased intake of polyamine seems to suppress tumorigenesis, but appears to accelerate the growth of established tumors. Based on these observations and the absolute requirement for polyamines in tumor growth, spermidine could be a rational target for chemoprevention and clinical therapeutics of cancers.

Keywords: Autophagy; Caloric restriction; Immunosurveillance; Spermidine; Tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Apoptosis
  • Autophagy
  • Biomarkers, Tumor / metabolism*
  • Cell Proliferation
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Predictive Value of Tests
  • Signal Transduction
  • Spermidine / antagonists & inhibitors
  • Spermidine / metabolism*

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Spermidine